OhioHealth Home  /  Services  /  Heart and Vascular  /  Our Programs  /  Heart Failure  /   /  Clinical Trials

Heart and Vascular

Heart Failure

Heart and Vascular

Heart Failure

Skip Menu

Heart Failure Clinical Trials

Advancing heart failure care with promising new therapies

Review active heart failure clinical trials at OhioHealth, the criteria for participation, and the steps to sign up.

Venus-HF

PI: Dr. Anupam Basuray

This clinical trial evaluates the safety and performance of the preCARDIA system as a therapeutic approach in significantly congested subjects with acute decompensated heart failure (ADHF). The system is intended to intermittently occlude the SVC to reduce preload to the heart in ADHF.

You may be eligible to participate in this trial if you:

  • Are indicated for right heart catheterization
  • Have an LVEF of <50%

AIM HIGHer

PI: Katherine Dodd, DO

Cardiac Contractility Modulation (CCM) is a device-based therapy for symptomatic heart failure. It is commercially approved for the treatment of heart failure with reduced ejection fraction (HFrEF).

Aim Higher is a clinical trial that investigates CCM therapy in patients with heart failure with preserved ejection fraction (HFpEF). All eligible subjects are implanted with the Optimizer Smart Mini System and randomized in a 2:1 ratio to either therapy ON or OFF.

You may be eligible to participate in this trial if you:

  • Have been diagnosed with heart failure
  • Are symptomatic
  • Have an LVEF of 40-60%

LEVEL

PI: Dr. Lindsay Castle

This trial is investigating an oral medication called Levosimendan and if it is effective in relieving PH-HFpEF symptoms, such as pressure in your heart or lungs. The study is randomized for the first 3 months. You will either receive Levosimendan or a placebo and you will not know which one you are taking. After 3 months, you can choose to remain in the study for up to 2 more years to receive only Levosimendan (no placebo).

You may be eligible to participate in this trial if you:

  • Have a diagnosis of PH-HFpEF
  • Have a left ventricular ejection fraction (LVEF) of at least 40%
  • Are aged 18-85 years old

Aspire-PH

PI: Dr. Lindsay Castle

Aspire-PH is a clinical trial assessing the treatment of pulmonary hypertension using the Aria CV Pulmonary Hypertension System. This system is intended to improve pulmonary arterial compliance in patients suffering from pulmonary hypertension and right heart dysfunction.

You may be eligible to participate in this trial if you:

  • Have pulmonary hypertension
  • Have right-heart dysfunction
  • Are symptomatic despite maximally tolerated GDMT

Interested in learning more? Call our Advanced Heart Failure Clinic at (614) 566-3150.